.
[This corrects the article DOI: 10.7759/cureus.112853.].
BACKGROUND:Failed back surgery syndrome (FBSS) describes persistent, recurrent, or new-onset low back pain and/or radicular symptoms following lumbar spine surgery. Revision lumbar surgery remains challenging because of altered anatomy, epidural scarring, unclear tissue planes, and a higher risk of complications. Careful identification of a surgically correctable pathology is essential to improve outcomes. AIM:The aim of this study was to evaluate the causes of failed previous lumbar surgery, indications for revision surgery, operative procedures performed, postoperative complications, and clinical and functional outcomes in patients undergoing revision lumbar spine surgery for FBSS. METHODS:This retrospective observational study included 150 patients who underwent revision lumbar spine surgery for FBSS between October 2017 and September 2023, with follow-up completed until September 2025. Patients were included if they had persistent or recurrent symptoms after previous lumbar surgery with radiological evidence of a surgically correctable pathology. Clinical data, operative findings, radiological diagnoses, complications, and follow-up outcomes were reviewed. Functional outcomes were assessed using the Visual Analogue Scale (VAS) and Oswestry Disability Index (ODI) preoperatively and at three, 12, and 24 months postoperatively. Statistical analysis was performed using IBM SPSS Statistics for Windows, version 29 (IBM Corp., Armonk, New York, United States), with p < 0.05 considered statistically significant. RESULTS:The study included 84 male and 66 female patients, with a mean age of 41 ± 10.09 years. The most common presenting symptom was sciatica, reported in 63 patients (42%), followed by low back pain with sciatica in 45 patients (30%). The most frequently revised level was L4/L5 in 48 patients (32%). Incomplete decompression was the most common cause of failed previous lumbar surgery, identified in 42 patients (28%), followed by recurrent disc herniation in 39 patients (26%), retained disc fragment in 36 patients (24%), pseudoarthrosis or instrumentation-related failure in 24 patients (16%), and wrong-level surgery in nine patients (6%). Perioperative complications occurred in 69 patients (46%), with dural tear being the most common complication in 24 patients (16%). At three months, 93 patients (62%) were pain-free, increasing to 105 patients (70%) at 12 months, and maintained at 24 months. Sensory improvement occurred in 15 of 48 patients (31%), while motor improvement occurred in 21 of 39 patients (53%). The mean VAS score improved from 7.22 ± 0.89 preoperatively to 0.98 ± 0.75 at 24 months, and the mean ODI improved from 66.30 ± 9.06 to 7.77 ± 3.55. Improvements in both VAS and ODI were statistically significant (p = 0.001). CONCLUSION:This study provides long-term evidence that revision lumbar surgery can achieve sustained improvements in pain and disability over 24 months in carefully selected patients with a surgically correctable pathology. It also demonstrates that potentially preventable technical factors, particularly incomplete decompression and retained disc fragments, represent important causes of failed previous surgery. These findings support the importance of accurate clinical-radiological correlation, careful patient selection, and meticulous surgical planning.
The importance of neoadjuvant systemic therapy in the treatment of HER2-positive breast cancer has become increasingly evident, particularly in the context of recent advancements in dual HER2 inhibition, which involves the administration of trastuzumab and pertuzumab. A pathological complete response (pCR) after treatment is considered a significant predictor of positive long-term outcomes for this subtype of tumour. The objective of this research is to evaluate the differences in pathological response outcomes between neoadjuvant therapies incorporating pertuzumab and those based solely on trastuzumab for patients diagnosed with HER2-positive breast cancer. A retrospective case-control analysis was performed on 75 individuals diagnosed with HER2-positive breast cancer at a tertiary oncology facility. Participants were divided into two groups: those who underwent therapy including pertuzumab and those who received treatment without it. The clinical, demographic and pathological data were meticulously documented, and pCR was evaluated following definitive surgical intervention. The statistical analyses encompassed chi-square tests and correlation assessments. The average age of participants was 52.5 ± 22.5 years, with a notable prevalence of women who had given birth (88%) and those with a history of breastfeeding (70.6%). Invasive ductal carcinoma constituted the predominant histological type (98.6%). Patients treated with pertuzumab-based neoadjuvant therapy exhibited significantly greater rates of pCR in comparison to those receiving regimens devoid of pertuzumab (80% vs. 48%, p = 0.007). Lymphovascular invasion (LVI) demonstrated a significant correlation with pCR among patients receiving pertuzumab (p = 0.005), while the administration of anthracycline-based regimens within this group indicated the highest probability of achieving a complete pathological response (p = 0.003). Neoadjuvant therapy incorporating pertuzumab has been demonstrated to result in a significant enhancement of pCR rates in patients diagnosed with HER2-positive breast cancer, in comparison with treatments comprising trastuzumab alone. These results support the hypothesis that dual HER2 blockade should be given preferential consideration, particularly in cases where anthracycline-based combinations are an option.Keywords: The following terms are used in this text: HER2-positive breast cancer, pertuzumab, neoadjuvant treatment, dual HER2 inhibition and pathological complete response.
Aim: This study aimed to compare bleeding rates, need for reoperation, transfusion requirements, and operative time between patients managed with clipping alone and those with the combined technique. Subjects and Methods: This prospective study was undertaken on patients who underwent sleeve gastrectomy for morbid obesity. Patients were divided into two equal groups. In the Clipping Group, only clipping was used as the hemostatic method. In the Combined Group, both clipping and electrocoagulation of vessels near the staple line were employed. A drainage volume exceeding 150 mL and a persistent pulse rate above 105 beats per minute were considered significant bleeding. Results: The study analyzed data from 1,000 patients who underwent laparoscopic sleeve gastrectomy (LSG). Blood transfusion was required in 5% from the clipping group compared with 1% in the combined group. A second surgical intervention was needed in 1.4% from the clipping group and only 0.2% in the combined group. No anastomotic leaks or mortalities were reported in either group. Postoperative bleeding was significantly higher in the clipping group. The average operation time was significantly longer in the clipping group. Conclusion: Electrocoagulation of vessels near the staple line, in addition to clipping, provides superior hemostatic control without increasing the postoperative complications.